Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

NCT06351904 is registered in ClinicalTrials.gov with Ractigen Therapeutics. as lead sponsor.

NCT NCT06351904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06351904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Lead sponsor
Ractigen Therapeutics.
Phase
Phase 1
Overall status
Recruiting
Start date
April 3, 2024
Completion date
August 31, 2028
Enrollment
72 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer (nmibc)